The KRAS oncogene is mutated in approximately 35–45 % of colorectal cancers and KRAS mutations are considered to be more predominant in pancreatic, thyroid, colorectal, and lung cancers [27, 28]. The gene discussed is KRAS; the disease is lung cancer.